Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia (Q38796312)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2016

Language	Label	Description	Also known as
English	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia	scientific article published on April 2016

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia (English)

1 reference

Europe PubMed Central

6 September 2017

1 reference

based on heuristic

inferred from title

metabolic syndrome

1 reference

based on heuristic

inferred from title

atherosclerosis

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.

0 references

author name string

Nicola Ferri

1

1 reference

Europe PubMed Central

6 September 2017

Massimiliano Ruscica

2

1 reference

Europe PubMed Central

6 September 2017

publication date

1 April 2016

1 reference

Europe PubMed Central

6 September 2017

1 reference

Europe PubMed Central

6 September 2017

54

1 reference

Europe PubMed Central

6 September 2017

588-601

1 reference

Europe PubMed Central

6 September 2017

3

1 reference

Europe PubMed Central

6 September 2017

https://scigraph.springernature.com/pub.10.1007/s12020-016-0939-0

0 references

Metabolic syndrome pandemic.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The regulation of ApoB metabolism by insulin

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

How to screen obese children at risk for type 2 diabetes mellitus?

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Insulin resistance and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Targeting inflammation in metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Adipocyte dysfunction, inflammation and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammation and atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The PCSK9 decade

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Precursor convertases in the secretory pathway, cytosol and extracellular milieu

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 function and physiology.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The LDL receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Molecular basis for LDL receptor recognition by PCSK9

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

SREBP transcription factors: master regulators of lipid homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Resistin: insulin resistance to malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

A new method for measurement of total plasma PCSK9: clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Fructose and metabolic diseases: new findings, new questions

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The effect of insulin on circulating PCSK9 in postmenopausal obese women

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Statin therapy and related risk of new-onset type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Role of PCSK9 beyond liver involvement

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The role of the LDL receptor in apolipoprotein B secretion

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Small dense LDL: An emerging risk factor for cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Small LDL-cholesterol is superior to LDL-cholesterol for determining severe coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

The composition and metabolism of large and small LDL.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes melli

1 reference

https://api.crossref.org/works/10.1007%2FS12020-016-0939-0

21 January 2018

Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertriglyceridemia and its metabolic consequences as a risk factor for atherosclerotic cardiovascular disease in non-insulin-dependent diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Québec Child and Adolescent Health and Social Survey: design and methods of a cardiovascular risk factor survey for youth

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are pleiotropic effects of statins real?

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women

1 reference

https://pubmed.ncbi.nlm.nih.gov/27038318

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12020-016-0939-0

1 reference

Europe PubMed Central

6 September 2017

release_ud43oc2amjfkpkman4ycwjy3je

1 reference

https://api.fatcat.wiki/v0/release/ud43oc2amjfkpkman4ycwjy3je

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

6 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38796312&oldid=1837803506"